Eli Lilly logo is shown on one of the company's ... The new investment, which will bring the company's cumulative investment in China to exceed 20 billion yuan ($2.81 billion), aims to boost ...

Eli Lilly is making a series of investments in China to support its manufacturing and R&D operations. Gilead Sciences has abandoned a liver disease collaboration with Yuhan. A new study suggests ...

opening two research centers called the Eli Lilly China Medical Innovation Center and Lilly Gateway Labs. The newest Gateway Lab is the second to set up shop outside of the U.S. following a ...

A recent study that found there has been a massive increase in type 2 diabetes cases worldwide since 1990 is an indication ...

Eli Lilly (NYSE:LLY) received approval from the ... The drug is potentially the first of its kind to become available in the China region. Lilly’s (LLY) shot has already been approved in ...

In my most recent article about Eli Lilly and Company, I reaffirmed the company as a 'hold' candidate. This was in spite of the fact that the business had achieved a big win in China and that ...

The latest celebrity weight-loss drug to be given the nod in Hong Kong will be available in December, but experts cautioned ...

Yet, Eli Lilly's GLP-1 medications are helping it compete ... A few months later, Wegovy was approved to enter yet another market: China, a geographic region where obesity rates are quite high.

Eli Lilly & Co. will set up a S$42 million ($31 million) digital health innovation hub in Singapore, expanding its research ...

It's the same story with stocks. We saw that happen with Eli Lilly (NYSE: LLY) this week. Lilly announced its third-quarter results on Wednesday. Investors didn't like what they heard. The big ...

Eli Lilly submitted marketing applications for mirikizumab for Crohn’s disease around the globe, including in the U.S., Canada, Europe, Japan, and China. Additionally, Eli Lilly has a ...